NANOBIOTIC TREATMENT FOR REVERSING ATHEROSCLEROSIS

THE PATHOGENESIS OF VASCULAR

CALCIFICATION, NEW CLINICAL

DIAGNOSTIC MARKERS AND A NEW

CURATIVE NANOBIOTIC TREATMENT

FOR REVERSING ATHEROSCLEROSIS

IN HUMANS.

 

 Kajander EO^1,2,3, Aho KM1, Maniscalco BS3, Mezo

^GS3, 1University of Kuopio, Kuopio, 2Nanobac Oy, Kuopio, Finland; 3NanobacLabs Research Institute, Tampa, USA

Background: Atherosclerosis is an inflammatory disease stimulated by various infectious agents. Our hypothesis is that nanobacteria (Nanobacterium sanguineum, Ns), a new self-replicating infectious calcifying agent found in human blood, which causes life-long infections and adversely affects human cells, is causing atherosclerosis in the human vasculature. Clinical efficacy of a new targeted nanobiotic medication to reverse calcified atherosclerotic plaques and microvascular disease was evaluated in patients with advanced heart disease.

Methods (1) Ns was screened with immunohistochemical staining in human aortic calcific plaques and with prospective epidemiological survey on Ns markers (Ag and Ab) done by Nyyssönen, Kajander, Ciftcioglu and Salonen. (2) Ns lipid, mineral and protein components and biological interactions were analyzed with focus on atherosclerosis. (3) NanobacTX-ACES Clinical Study was undertaken to document the efficacy of the new nanobiotic, NanobacTX, to reverse coronary artery plaque calcification in 90 patients with well-documented coronary artery disease and high levels of coronary artery calcification. 4-month treatment outcome of NanobacTX was followed with EBCT Coronary Artery Calcification Scoring and with Ns markers in blood. Other medications or diet were not changed during the Study.

Results: Immunohistochemical staining detected Ns in 2 out of 4 aortic calcific plaques verifying results from the Mayo Clinic (Rasmunssen et al. JACC 39 Suppl: 206, 2002) and Puskas (Nanobacteria Minisymposium, http://www.nanobac.com/nbminisymp080301/page13.html). The Epidemiological Study found an association between Ns antigen and risk of MI and stroke. Ns biofilm contains Ca2+, unique lipopolysaccaride (LPS) and prothrombin, known active components of inflammatory and clotting processes. The NanobacTX-ACES Nanobiotic Study showed decreases in Coronary Artery Calcification EBCT scores by an average of 58% in Study subjects. Ns antigen and antibody showed a trend to rise at 2 months and to fall after 4 months.

Conclusions: Immunohistochemical staining showed presence of Ns in human aortic calcific plaques. Ns markers in blood have prognostic value for risk of MI and stroke. Ns contains components capable of stimulating immune cascades leading to local tissue/vascular wall inflammation and are risk factors for arterial and venous thrombus formation. Our earlier animal studies have revealed thrombus formation in large veins and arteries after Ns injection. Nanobiotic treatment with NanobacTX was effective in reversing coronary artery calcification. NanobacTX treatment caused initial increase in Ns markers leading to decline with concomitant improvement of atherosclerotic calcification scores in EBCT. Findings of the study open new insights to pathogenesis, diagnostics and treatment of atherosclerosis. Further research is clearly warranted.

In: XXIV Tampereen Lääkäripäivät 20.–22.3.2003 Luennot XXIV. Eds. Anttila S, Antonen J, Hutri-Kähönen N, Lahtela J, Tomas E, Anttila P. Lege Artis Oy, Tampere. Vammalan Kirjapaino Oy, Vammala 2003, p.330.

Kajander EO, Aho KM, Maniscalco BS, Mezo GS. THE PATHOGENESIS OF VASCULAR CALCIFICATION, NEW CLINICAL DIAGNOSTIC MARKERS AND A NEW CURATIVE NANOBIOTIC TREATMENT FOR REVERSING ATHEROSCLEROSIS IN HUMANS. 24th Tampere Medical Symposium, March 20-22, 2003, Tampere, Finland. The Organizing Committee of Tampere Medical Symposium 2003, Abstract Book, page 330 abstract No.2. Publisher Lege Artis Oy, Tampere.